Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial

October 2021 in “ Clinical, Cosmetic and Investigational Dermatology ”

Janet DuBois, Suzanne Bruce, Daniel Stewart, Steven Kempers, Christy Harutunian, Terry Boodhoo, Amy Weitzenfeld, Joan-En Chang-Lin

setipiprant CRTH2 antagonist androgenetic alopecia finasteride placebo AGA Propecia

TLDR Setipiprant did not significantly improve hair growth in men with hair loss.

The study evaluated the efficacy and safety of setipiprant, a CRTH2 antagonist, for treating androgenetic alopecia (AGA) in 169 men over 24 weeks. Results showed no significant improvement in hair growth with setipiprant compared to placebo, although it was well tolerated. Finasteride, used as an unblinded reference, showed greater numerical improvements in hair count but was not formally compared. The study concluded that setipiprant did not significantly enhance hair growth in men with AGA.

View this study on dovepress.com →

Discuss this study in the Community →

Research cited in this study

17 / 17 results

research Safety Concerns When Using Novel Medications to Treat Alopecia

23 citations, October 2018 in “Expert Opinion on Drug Safety”

Consider benefits and risks of new alopecia treatments for safety.

research Evidence-Based Guideline for the Treatment of Androgenetic Alopecia in Women and Men – Short Version

145 citations, November 2017 in “Journal of The European Academy of Dermatology and Venereology”

Use minoxidil for hair loss treatment; assess results after 6 months.

research Multi-Therapies in Androgenetic Alopecia: Review and Clinical Experiences

55 citations, July 2016 in “Dermatologic Therapy”

Multiple treatments work best for hair loss.

research Does Prostaglandin D2 Hold the Cure to Male Pattern Baldness?

57 citations, February 2014 in “Experimental Dermatology”

Prostaglandin D₂ might be targeted for new male pattern baldness treatments.

A Randomized, Active- and Placebo-Controlled Study of the Efficacy and Safety of Different Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects with Androgenetic Alopecia

research A Randomized, Active- and Placebo-Controlled Study of the Efficacy and Safety of Different Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects with Androgenetic Alopecia

97 citations, January 2014 in “Journal of The American Academy of Dermatology”

Dutasteride 0.5 mg works better than finasteride and placebo for increasing hair in men with hair loss.

Prostaglandin D2 Inhibits Wound-Induced Hair Follicle Neogenesis Through the Receptor Gpr44

research Male Androgenetic Alopecia

100 citations, April 2010 in “Expert Opinion on Pharmacotherapy”

Hair loss in men treated best with early medication or transplant, new treatments researched.

The Importance of Dual 5α-Reductase Inhibition in the Treatment of Male Pattern Hair Loss: Results of a Randomized Placebo-Controlled Study of Dutasteride Versus Finasteride

research The Importance of Dual 5α-Reductase Inhibition in the Treatment of Male Pattern Hair Loss: Results of a Randomized Placebo-Controlled Study of Dutasteride Versus Finasteride

215 citations, November 2006 in “Journal of The American Academy of Dermatology”

Dutasteride more effective for hair growth, but has more side effects than finasteride.

research Psychological Effect, Pathophysiology, and Management of Androgenetic Alopecia in Men

112 citations, October 2005 in “Mayo Clinic Proceedings”

Minoxidil and finasteride can slow hair loss and stimulate regrowth, but won't restore all lost hair or reverse complete baldness.

A Randomized Clinical Trial of 5% Topical Minoxidil Versus 2% Topical Minoxidil and Placebo in the Treatment of Androgenetic Alopecia in Men

research A Randomized Clinical Trial of 5% Topical Minoxidil Versus 2% Topical Minoxidil and Placebo in the Treatment of Androgenetic Alopecia in Men

269 citations, August 2002 in “Journal of The American Academy of Dermatology”

5% minoxidil works better for hair growth and density, with minor irritation.

research Prostaglandin-Induced Hair Growth

162 citations, August 2002 in “Survey of Ophthalmology”

Latanoprost can make eyelashes longer, thicker, and darker.

research Clinical Dose Ranging Studies with Finasteride, a Type 2 5α-Reductase Inhibitor, in Men with Male Pattern Hair Loss

46 citations, October 1999 in “Journal of The American Academy of Dermatology”

Finasteride effectively treats male pattern hair loss with a 1 mg daily dose.

research Finasteride, a Type 2 5α-Reductase Inhibitor, in the Treatment of Men with Androgenetic Alopecia

32 citations, April 1999 in “Expert Opinion on Investigational Drugs”

Finasteride effectively treats male hair loss, improving growth and density.

research The Psychological Effects of Androgenetic Alopecia in Men

192 citations, June 1992 in “Journal of The American Academy of Dermatology”

Hair loss can cause low self-esteem, anxiety, and depression in men.

Related Research

1 / 1 results

research Progression of Hair Loss in Men With Androgenetic Alopecia: Long-Term Controlled Observational Data in Placebo-Treated Patients

9 citations, June 2008

Men with untreated male pattern hair loss continue to lose hair over a 5-year period.

Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial

Research cited in this study

research Safety Concerns When Using Novel Medications to Treat Alopecia

research Evidence-Based Guideline for the Treatment of Androgenetic Alopecia in Women and Men – Short Version

research Multi-Therapies in Androgenetic Alopecia: Review and Clinical Experiences

research Does Prostaglandin D2 Hold the Cure to Male Pattern Baldness?

research A Randomized, Active- and Placebo-Controlled Study of the Efficacy and Safety of Different Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects with Androgenetic Alopecia

research Prostaglandin D2 Inhibits Wound-Induced Hair Follicle Neogenesis Through the Receptor Gpr44

research The Prostamide-Related Glaucoma Therapy, Bimatoprost, Offers a Novel Approach for Treating Scalp Alopecias

research Prostaglandin D2 Inhibits Hair Growth and Is Elevated in Bald Scalp of Men with Androgenetic Alopecia

research Efficacy and Safety of Finasteride Therapy for Androgenetic Alopecia

research Male Androgenetic Alopecia

research The Importance of Dual 5α-Reductase Inhibition in the Treatment of Male Pattern Hair Loss: Results of a Randomized Placebo-Controlled Study of Dutasteride Versus Finasteride

research Psychological Effect, Pathophysiology, and Management of Androgenetic Alopecia in Men

research A Randomized Clinical Trial of 5% Topical Minoxidil Versus 2% Topical Minoxidil and Placebo in the Treatment of Androgenetic Alopecia in Men

research Prostaglandin-Induced Hair Growth

research Clinical Dose Ranging Studies with Finasteride, a Type 2 5α-Reductase Inhibitor, in Men with Male Pattern Hair Loss

research Finasteride, a Type 2 5α-Reductase Inhibitor, in the Treatment of Men with Androgenetic Alopecia

research The Psychological Effects of Androgenetic Alopecia in Men

Related Community Posts Join

community The New, Improved CB-03-01/Setipiprant Group Buy

community SETIPIPRANT PGE2 GROUP BUY AND PIONEERING HAIR GROWTH

community Fevipiprant 2019!

community Setipiprant trial results

community Setipiprant study updated on ClinicalTrials - anticipated May 9th completion

community Upcoming Setipiprant clinical trials hint at systemic daily dosage

Related Research

research Progression of Hair Loss in Men With Androgenetic Alopecia: Long-Term Controlled Observational Data in Placebo-Treated Patients